Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis

Free Subscription 26.09.2022 1 AIDS 1 Arch Virol 1 BMC Gastroenterol 1 Clin Infect Dis 1 Dig Dis Sci 3 Hepatology 4 J Hepatol 1 J Infect Dis 3 J Viral Hepat 2 J Virol 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AIDS

1. STONE J, Fraser H, Walker JG, Mafirakureva N, et al
   Modelling the impact of HIV and HCV prevention and treatment interventions among people who inject drugs in Kenya.
   AIDS. 2022 Sep 15. pii: 00002030-990000000-00111.
   PubMed         Abstract available
   
   

   
   Arch Virol

2. ABD-ELSALAM S, Sharaf-Eldin M, Soliman S, Elfert A, et al
   Retraction Note to: Efficacy and safety of sofosbuvir plus ribavirin for treatment of cirrhotic patients with genotype 4 hepatitis C virus in real-life clinical practice.
   Arch Virol. 2022 Sep 20. pii: 10.1007/s00705-022-05600.
   PubMed        
   
   

   
   BMC Gastroenterol

3. CHANG SS, Hu HY, Chen YC, Yen YF, et al
   Late hepatitis C virus diagnosis among patients with newly diagnosed hepatocellular carcinoma: a case-control study.
   BMC Gastroenterol. 2022;22:425.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

4. BALIASHVILI D, Blumberg HM, Benkeser D, Kempker RR, et al
   Association of treated and untreated chronic hepatitis C with the incidence of active tuberculosis disease: a population-based cohort study.
   Clin Infect Dis. 2022 Sep 22. pii: 6711147. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

5. HONMA Y, Shibata M, Morino K, Koya Y, et al
   Impact of Interferon-Free Direct-Acting Antivirals on the Incidence of Extrahepatic Malignancies in Patients with Chronic Hepatitis C.
   Dig Dis Sci. 2022 Sep 14. pii: 10.1007/s10620-022-07686.
   PubMed         Abstract available
   
   

   
   Hepatology

6. MAK LY, Hui RW, Lee CH, Mao X, et al
   Glycemic burden and the risk of adverse hepatic outcomes in patients with chronic hepatitis B with type 2 diabetes.
   Hepatology. 2022 Sep 21. doi: 10.1002/hep.32716.
   PubMed         Abstract available
   
   
7. JACHS M, Tillmann HL
   Editorial: It's not all about the virus - on the importance of modifiable lifestyle factors in the development of hepatocellular carcinoma in chronic hepatitis B.
   Hepatology. 2022 Sep 17. doi: 10.1002/hep.32798.
   PubMed        
   
   
8. YING D, He Q, Tian W, Chen Y, et al
   Urine Is a Viral Antigen Reservoir in Hepatitis E Virus Infection.
   Hepatology. 2022 Sep 15. doi: 10.1002/hep.32745.
   PubMed         Abstract available
   
   

   
   J Hepatol

9. LURZ E, Lenz D, Bufler P, Fichtner A, et al
   Letter to the editor - A peditatric hepatologists' perspective.
   J Hepatol. 2022 Jun 14. pii: S0168-8278(22)00363.
   PubMed        
   
   
10. LEE SK, Kwon JH, Yoon N, Lee SH, et al
    Immune-mediated liver injury represented as overlap syndrome after SARS-CoV-2 vaccination.
    J Hepatol. 2022;77:1209-1211.
    PubMed        
    
    
11. MARTIN-NAVARRO L, de Andrea C, Sangro B, Argemi J, et al
    In situ detection of vaccine mRNA in the cytoplasm of hepatocytes during COVID19 vaccine-related hepatitis.
    J Hepatol. 2022 Sep 15. pii: S0168-8278(22)03076.
    PubMed        
    
    
12. AGARWAL K, Lok J, Gane E
    Antisense oligonucleotides (ASOs) in chronic hepatitis B infection: Opportunities and challenging the orthodoxy.
    J Hepatol. 2022;77:906-908.
    PubMed        
    
    

    
    J Infect Dis

13. HALL SA, Burns GS, Mooney BJ, Millen R, et al
    Hepatitis B Virus Flares following Nucleot(s)ide Analogue Cessation Are Associated with Activation of TLR Signalling Pathways.
    J Infect Dis. 2022 Sep 15. pii: 6701634. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Viral Hepat

14. CAREY I, Christiana M, Marie-Ange M, Teresa B, et al
    Universal versus targeted screening for HCV infection in pregnancy in a diverse, multi-ethnic population: universal screening is more comprehensive.
    J Viral Hepat. 2022 Sep 22. doi: 10.1111/jvh.13752.
    PubMed         Abstract available
    
    
15. CHOU C, Veracruz N, Chitnis AS, Wong RJ, et al
    Risk of Drug Induced Liver Injury in Chronic Hepatitis B and Tuberculosis Co-infection: A Systematic Review and Meta-Analysis.
    J Viral Hepat. 2022 Sep 22. doi: 10.1111/jvh.13751.
    PubMed         Abstract available
    
    
16. MCDANIEL K, Utz AE, Akbashev MY, Fuller K, et al
    Safe co-administration of direct-acting antivirals and direct oral anticoagulants among patients with hepatitis C virus infection: an international multicenter retrospective cohort study.
    J Viral Hepat. 2022 Sep 14. doi: 10.1111/jvh.13750.
    PubMed         Abstract available
    
    

    
    J Virol

17. KIM GW, Moon JS, Gudima SO, Siddiqui A, et al
    N(6)-Methyladenine Modification of Hepatitis Delta Virus Regulates Its Virion Assembly by Recruiting YTHDF1.
    J Virol. 2022 Sep 14:e0112422. doi: 10.1128/jvi.01124.
    PubMed         Abstract available
    
    
18. SOORYANARAIN H, Heffron CL, Mahsoub HM, Hassebroek AM, et al
    Modulation of SOCS3 Levels via STAT3 and Estrogen-ERalphap66 Signaling during Hepatitis E Virus Replication in Hepatocellular Carcinoma Cells.
    J Virol. 2022 Sep 14:e0100822. doi: 10.1128/jvi.01008.
    PubMed         Abstract available
    
    

    
    PLoS One

19. YOKOKAWA H, Shinohara M, Teraoka Y, Imamura M, et al
    Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants.
    PLoS One. 2022;17:e0274283.
    PubMed         Abstract available
    
    
20. WANG P, Zhang L, He J, Zhang G, et al
    Accuracy of hepatitis B disease surveillance, Gannan prefecture, Gansu province, China; 2017.
    PLoS One. 2022;17:e0274798.
    PubMed         Abstract available
    
    
21. HEREDIA JE, Sorenson C, Flanagan S, Nunez V, et al
    IL-23 signaling is not an important driver of liver inflammation and fibrosis in murine non-alcoholic steatohepatitis models.
    PLoS One. 2022;17:e0274582.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: